Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) just unveiled an announcement.
Jiangsu Recbio Technology Co., Ltd. has announced the current composition of its board of directors, led by chairman and non-executive director Xu Haoyu, and including a mix of executive, non-executive and independent non-executive directors such as Liu Yong, Wei Qifang and several academic and industry experts. The company has also detailed the structure and membership of its three key board committees—Audit, Remuneration and Appraisal, and Nomination—assigning independent director Xia Lijun and professors Gao Feng and Yuen Ming Fai to chair these committees, in a move that underscores its emphasis on governance, oversight and professionalized decision-making as it continues to develop its business in the biopharmaceutical industry.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a joint stock company incorporated in Jiangsu Province, the People’s Republic of China, and is listed in Hong Kong under stock code 2179. The company operates in the biopharmaceutical sector, focusing on vaccine and related biotechnology research, development and commercialization for domestic and international healthcare markets.
Average Trading Volume: 48,308
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.43B
Find detailed analytics on 2179 stock on TipRanks’ Stock Analysis page.